LONDON – Abbvie Inc. has withdrawn the legal case it took out to prevent the EMA from publishing the clinical study reports relating to its anti-TNF alpha drug, Humira (adalimumab), after the agency accepted a new set of redacted documents and agreed with the company’s rationale for removing certain commercially confidential information from the reports at the center of the litigation.